John Maxwell Net Worth

The estimated Net Worth of John T. Maxwell is at least $1.82 Million dollars as of 18 August 2020. Mr. Maxwell owns over 3,000 units of Aquestive Therapeutics Inc stock worth over $745,539 and over the last 6 years he sold AQST stock worth over $24,000. In addition, he makes $1,054,120 as Senior Vice President and Chief Financial Officer at Aquestive Therapeutics Inc.

Wallmine is a radically better financial terminal.
Sign up in seconds, it's free!

Sign up

Already have an account? Sign in

Mr. Maxwell AQST stock SEC Form 4 insiders trading

John has made over 3 trades of the Aquestive Therapeutics Inc stock since 2018, according to the Form 4 filled with the SEC. Most recently he sold 3,000 units of AQST stock worth $24,000 on 18 August 2020.

The largest trade he's ever made was buying 10,000 units of Aquestive Therapeutics Inc stock on 21 November 2018 worth over $98,000. On average, John trades about 3,000 units every 106 days since 2018. As of 18 August 2020 he still owns at least 150,614 units of Aquestive Therapeutics Inc stock.

You can see the complete history of Mr. Maxwell stock trades at the bottom of the page.

John Maxwell biography

John T. Maxwell CPA serves as Senior Vice President, Chief Financial Officer of the Company. Mr. Maxwell has served as our Senior Vice President - Chief Financial Officer since January 2017. Prior to joining our team, Mr. Maxwell held senior financial roles at WIL Research, InfoNXX, PanAmSat, ADP and General Signal, including, most recently, as Chief Financial Officer of WIL Research from September 2008 to April 2016. In addition, Mr. Maxwell served as a consultant from April 2016 until January 2017. Mr. Maxwell started his career at Ernst & Young, serving in the Dallas, New York and Stamford offices. Mr. Maxwell helped lead the successful strategic sale transactions by the private equity sponsors of WIL Research in April 2016 to Charles River Labs and of PanAmSat in 2006 to Intelsat. Mr. Maxwell also helped lead the initial public offering of PanAmSat in 2005 and multiple public and private debt transactions for WIL Research, InfoNXX and PanAmSat. Mr. Maxwell is a licensed certified public accountant and holds a B.B.A in Accounting from Texas Tech University and an M.B.A in Finance and International Business from New York University Stern School of Business.

What is the salary of John Maxwell?

As the Senior Vice President and Chief Financial Officer of Aquestive Therapeutics Inc, the total compensation of John Maxwell at Aquestive Therapeutics Inc is $1,054,120. There are 3 executives at Aquestive Therapeutics Inc getting paid more, with A. Mark Schobel having the highest compensation of $7,575,660.

How old is John Maxwell?

John Maxwell is 55, he's been the Senior Vice President and Chief Financial Officer of Aquestive Therapeutics Inc since 2017. There are 16 older and 4 younger executives at Aquestive Therapeutics Inc. The oldest executive at Aquestive Therapeutics Inc is Gregory Brown, 66, who is the Independent Director.

What's John Maxwell's mailing address?

John's mailing address filed with the SEC is C/O AQUESTIVE THERAPEUTICS, INC., 30 TECHNOLOGY DRIVE, WARREN, NJ, 07059.

Insiders trading at Aquestive Therapeutics Inc

Over the last 6 years, insiders at Aquestive Therapeutics Inc have traded over $1,898,648 worth of Aquestive Therapeutics Inc stock and bought 370,463 units worth $3,088,399 . The most active insiders traders include Marco Taglietti, Nancy Lurker, and Alexander Mark Schobel. On average, Aquestive Therapeutics Inc executives and independent directors trade stock every 36 days with the average trade being worth of $77,928. The most recent stock trade was executed by Alexander Mark Schobel on 15 March 2024, trading 50,000 units of AQST stock currently worth $300,000.

What does Aquestive Therapeutics Inc do?

aquestive therapeutics is a specialty pharmaceutical company that advances and commercializes medicines to solve critical healthcare problems and meaningfully improve people’s lives. our team asks questions and identifies issues others have not, and builds solutions that empower patients and their caregivers with better ways to manage complex diseases. our initial focus, supported by our current approved products and late stage pipeline, is to address immediate cns challenges.

Complete history of Mr. Maxwell stock trades at Aquestive Therapeutics Inc

Aquestive Therapeutics Inc executives and stock owners

Aquestive Therapeutics Inc executives and other stock owners filed with the SEC include:

• A. Mark Schobel,
  Chief Innovation and Technology Officer
• Keith Kendall,
  President, Chief Executive Officer, Director
• Daniel Barber,
  Chief Operating Officer, Senior Vice President
• John Maxwell,
  Senior Vice President, Chief Financial Officer
• Keith J. Kendall,
  CEO, Pres & Director
• Daniel Barber,
  Sr. VP & COO
• Santo Costa,
  Independent Chairman of the Board
• James Scibetta,
  Independent Director
• Douglas Bratton,
  Independent Director
• Nancy Lurker,
  Independent Director
• Gregory Brown,
  Independent Director
• John Cochran,
  Vice Chairman of the Board
• Gary Slatko,
  Senior Vice President, Chief Medical Officer
• Kenneth Marshall,
  Senior Vice President - Chief Commercial Officer
• Peter Boyd,
  Senior Vice President - Business Process and Information Technology
• Theresa Wood,
  Senior Vice President - Human Resources and Organizational Development
• Lori Braender,
  Senior Vice President - General Counsel, Chief Compliance Officer and Corporate Secretary
• Dr. Gary H. Slatko M.D., MBA,
  Sr. VP & Chief Medical Officer
• Kenneth W. Marshall,
  Sr. VP & Chief Commercial Officer
• Peter E. Boyd,
  Sr. VP of Bus. Process & Information Technology
• Dr. Eric Dadey Ph.D.,
  Sr. Vice-Pres of R&D
• Theresa Wood,
  Sr. VP of HR & Organizational Devel.
• Lori J. Braender Esq.,
  Sr. VP, Gen. Counsel, Chief Compliance Officer & Corp. Sec.
• Alexander Mark Schobel,
  Chief Innovation & Technology Officer
• A. Ernest Toth Jr.,
  Sr. VP & CFO
• Timothy E Morris,
  
• Ken W. Marshall,
  SVP, Chief Commercial Officer
• Marco Taglietti,
  
• Julie Krop,
  
• Douglas K Monoline Partners...,
  
• Cassie Jung,
  SVP, Operations
• Douglas K Mono Line Partner...,
  
• Kenneth Truitt,
  Chief Medical Officer
• A Ernest Jr Toth,
  SVP, Chief Financial Officer
• Carl N Kraus,
  Chief Medical Officer
• Stephen Wargacki,
  Chief Science Officer
• Abigail L. Jenkins,
  
• Sherry Korczynski,
  SVP Sales and Marketing